{"entity":{"id":"investigator-initiated-trials","kind":"term","name":"Investigator-initiated trials and study responsibilities","aka":["investigator-initiated trial","investigator-sponsored study","sponsor-investigator"],"tldr":"A researcher can originate a study while its sponsor, investigators, supplier and funders have distinct responsibilities. The protocol and regulatory arrangement identify who does what.","summary":"Investigator-initiated describes the origin of a study, not its phase, evidence strength or authorization. Under U.S. drug-investigation rules, a sponsor initiates and takes responsibility for the investigation; an investigator conducts it. An individual sponsor-investigator has both sets of responsibilities. An academic institution can also sponsor a study. Product supply or funding alone should not be used to infer the regulatory sponsor. The proposed protocol determines whether an IND or another applicable arrangement is needed.","asOf":"2026-11-08","links":[{"label":"21 CFR 312.3: sponsor and investigator definitions","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.3"},{"label":"21 CFR 312.2: applicability and exemptions","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.2"},{"label":"FDA: IND exemption criteria","url":"https://www.fda.gov/drugs/investigational-new-drug-application-ind/ind-application-procedures-exemptions-ind-requirements"},{"label":"FDA: Investigational New Drug application","url":"https://www.fda.gov/drugs/types-applications/investigational-new-drug-application-ind"}],"tags":[],"related":["investigational-new-drug-application","clinical-trial","trial-protocol","expanded-access","off-label"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A study of a lawfully marketed drug is IND-exempt only when all applicable exemption conditions are met. These include the study purpose, risk implications of dose, route or population, and required ethics review and informed consent. Academic origin or approved-drug status alone does not establish exemption."],"category":"Regulation & policy"},"route":"/terms/investigator-initiated-trials/","neighbours":{"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/"},{"id":"investigational-new-drug-application","kind":"term","name":"Investigational New Drug application","route":"/terms/investigational-new-drug-application/"},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/"},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/"}]}}